Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499433 | 0.85 | HPGD (0.35) | HPGDALDH1A1 | |
| SCHEMBL4526651 | 0.82 | KEAP1 (0.52) | KEAP1SMN1; SMN2MAPK1HIF1AHPGD | |
| SCHEMBL5419101 | 0.77 | KEAP1 (0.47) | KEAP1SMN1; SMN2MAPK1HIF1AHPGD | |
| SCHEMBL6161463 | 0.77 | CXCR4 (0.39) | SMN1; SMN2HPGDPOLBSIGMAR1KDM1A | |
| SCHEMBL15515228 | 0.74 | KDM4E (0.45) | KEAP1SMN1; SMN2MAPK1HIF1AHPGD | |
| SCHEMBL6408637 | 0.72 | KEAP1 (0.58) | KEAP1SMN1; SMN2MAPK1HIF1AHPGD | |
| SCHEMBL27866521 | 0.72 | KEAP1 (0.48) | KEAP1SMN1; SMN2MAPK1HPGDDUSP3 | |
| SCHEMBL7291045 | 0.71 | KEAP1 (0.52) | KEAP1SMN1; SMN2MAPK1HIF1AHPGD | |
| SCHEMBL6764986 | 0.70 | KEAP1 (0.50) | KEAP1SMN1; SMN2MAPK1HIF1AHPGD | |
| SCHEMBL7294030 | 0.70 | KEAP1 (0.50) | KEAP1SMN1; SMN2MAPK1HIF1AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | KEAP1 3355/4885SMN1; SMN2 2546/4885MAPK1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.